Immune-Repertoire States in Autoimmune Disease

Abstract

The landscape of immune-repertoire states in autoimmune disease is increasingly recognized as central to understanding disease pathogenesis, progression, and therapeutic response. This review synthesizes current evidence on the composition and dynamics of the immune repertoire—particularly T and B cell receptor diversity—in various autoimmune disorders. Emphasis is placed on the clinical implications of repertoire skewing, clonal expansions, and their association with disease activity and prognosis. Recent advances in high-throughput sequencing have enabled unprecedented insights, supporting the development of precision diagnostics and targeted therapies. This article aims to provide clinicians and researchers with an updated, mechanism-based overview to inform patient management and future research.

Introduction

Autoimmune diseases represent a spectrum of chronic conditions characterized by aberrant immune responses against self-antigens, resulting in tissue damage and variable clinical manifestations. The immune repertoire, defined by the diversity and specificity of T cell receptors (TCRs) and B cell receptors (BCRs), underpins the immune system’s ability to distinguish self from non-self. Disruptions in repertoire composition, clonal selection, and loss of tolerance are increasingly recognized as central features in the pathogenesis of autoimmunity. Advances in next-generation sequencing (NGS) technologies have enabled detailed characterization of immune-repertoire states, offering novel biomarkers for disease activity and guiding the development of targeted therapies. This review consolidates current knowledge on immune-repertoire dynamics across major autoimmune diseases, highlighting clinical applications and future directions.

Epidemiology / Disease Burden

Autoimmune diseases collectively affect up to 5-8% of the population globally, with higher prevalence in women and certain ethnic groups. Major conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), type 1 diabetes mellitus (T1DM), and multiple sclerosis (MS) contribute significantly to morbidity, healthcare utilization, and socioeconomic burden. The chronic, relapsing nature of these diseases often necessitates lifelong immunomodulatory therapy, highlighting the need for better biomarkers and targeted interventions, for which immune-repertoire profiling is increasingly utilized in both research and clinical settings.

Pathophysiology

The immune repertoire in health is shaped by V(D)J recombination, somatic hypermutation, and thymic selection, resulting in a diverse array of TCRs and BCRs capable of recognizing myriad antigens. In autoimmunity, defects in central and peripheral tolerance mechanisms allow autoreactive clones to escape deletion. Studies have shown oligoclonal expansions and skewing of TCR and BCR repertoires in affected tissues and peripheral blood of patients with SLE, RA, MS, and T1DM. For instance, restricted TCR Vβ usage and dominant BCR clonotypes are commonly observed, correlating with disease activity. Molecular mimicry, epitope spreading, and bystander activation further drive repertoire changes, perpetuating chronic inflammation and tissue injury.

Risk Factors

Genetic predisposition (e.g., HLA haplotypes), environmental exposures (viral infections, smoking), and hormonal influences contribute to aberrant immune-repertoire states in autoimmune disease. Polymorphisms affecting antigen processing, TCR/BCR signaling, and regulatory T cell function can predispose to repertoire skewing and loss of tolerance. Additionally, age-related thymic involution and chronic antigenic stimulation (e.g., persistent infections) may further reduce repertoire diversity, enhancing susceptibility to autoimmunity.

Clinical Features

Clinically, repertoire alterations manifest variably across autoimmune diseases. In MS, oligoclonal bands in cerebrospinal fluid reflect B cell clonal expansion. In SLE, expanded autoreactive BCR clones correlate with disease flares and nephritis. RA patients may exhibit restricted TCR repertoires in synovial tissue, associated with more severe joint involvement. These repertoire changes often parallel serological markers (e.g., autoantibodies) and can inform prognosis and risk stratification in clinical practice.

Diagnosis

Traditionally, diagnosis of autoimmune diseases relies on clinical, serological, and histopathological criteria. With the advent of high-throughput immune repertoire sequencing, novel diagnostic approaches are emerging. Identification of disease-specific clonal expansions or repertoire signatures can support early diagnosis, differentiate disease subtypes, and monitor minimal residual disease. For example, TCR/BCR sequencing is increasingly applied in the differential diagnosis of atypical autoimmune presentations and in monitoring therapeutic responses.

Treatment & Management

Management of autoimmune diseases traditionally involves immunosuppressive or immunomodulatory agents, such as corticosteroids, DMARDs, and biologics targeting cytokines or immune checkpoints. Understanding immune-repertoire states allows for precision medicine approaches—identifying patients likely to respond to specific therapies or at risk for adverse events. For instance, patients with persistent clonal expansions may benefit from B cell-depleting therapies (e.g., rituximab) or T cell-directed agents. Monitoring repertoire normalization during therapy may also inform treatment adjustments and predict sustained remission.

Recent Advances / Emerging Therapies

Recent years have witnessed rapid progress in immune repertoire profiling through single-cell sequencing, deep learning analytics, and integration with multi-omic datasets. These advances enable characterization of autoreactive clones and their functional phenotypes at unprecedented resolution. Emerging therapies, including peptide-based tolerogenic vaccines, adoptive regulatory T cell transfer, and antigen-specific B cell depletion, are being developed based on repertoire insights. Additionally, personalized neoantigen identification and engineered TCR/BCR therapies offer promise for refractory cases. Ongoing clinical trials are evaluating the utility of repertoire-guided therapy selection and monitoring in routine practice.

Guideline Recommendations

Current clinical guidelines from organizations such as the American College of Rheumatology and the European League Against Rheumatism emphasize the importance of early diagnosis, risk stratification, and individualized therapy in autoimmune diseases. While immune-repertoire profiling is not yet standard of care, expert consensus supports its research use for biomarker discovery and therapeutic development. As evidence accumulates, future guidelines are expected to incorporate repertoire-based diagnostics and monitoring strategies, particularly in refractory or atypical disease subsets.

Conclusion

The characterization of immune-repertoire states has transformed understanding of autoimmune disease mechanisms, with direct implications for diagnosis, prognosis, and therapy. Continued integration of repertoire profiling into clinical practice promises to enhance precision medicine approaches, improve patient outcomes, and guide the development of novel, mechanism-based treatments. As technology and analytical methods evolve, immune-repertoire insights will become increasingly central to the management of autoimmune disorders.